What is NephroGenex?
NephroGenex, Inc. is at the forefront of developing novel drug candidates for the treatment of kidney diseases, with a particular focus on diabetic nephropathy. Their lead compound, PYRIDORIN® (pyridoxamine dihydrochloride), is designed to mitigate the oxidative chemistries that accelerate the progression of diabetic nephropathy and end-stage renal disease. The company's efforts have garnered attention from regulatory bodies, evidenced by FDA Fast Track designation and Special Protocol Assessment for its Phase 3 Pyridorin program. This designation highlights the potential of PYRIDORIN® to serve as a breakthrough therapy in a therapeutic area with a significant unmet medical need, targeting patients afflicted by chronic kidney disease and acute kidney injury.
How much funding has NephroGenex raised?
NephroGenex has raised a total of $37.2M across 1 funding round:
Stock Offering
$37.2M
Stock Issuance/Offering (2014): $37.2M, investors not publicly disclosed
What's next for NephroGenex?
The substantial enterprise-level funding and recent strategic investment position NephroGenex for accelerated development and potential commercialization of PYRIDORIN®. With FDA Fast Track designation, the company is poised to navigate the regulatory pathway more efficiently, aiming to bring a much-needed therapeutic option to patients suffering from kidney diseases. The capital infusion will likely support the advancement of its Phase 3 trials, further clinical research, and potential expansion of its drug development pipeline. This strategic backing signals a strong belief in NephroGenex's scientific approach and its capacity to address critical challenges in nephrology.
See full NephroGenex company page
